Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIM: Acellular Pertussis Vaccine on Colonisation With Bordetella Pertussis
NCT06903221Phase 4Active, not recruiting
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of tetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccine in pertussis. Started Oct 2024; status: active, not recruiting.
02
Drugs
tetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccine
03
Conditions
pertussis
Beyond the preview
Go deeper on NCT06903221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06903221.